Financial statements Notes to the financial statements 31 Contingent liabilities At 31 December 2013, contingent liabilities, comprising guarantees, discounted bills and other items arising in the normal course of business, amounted to 198 million 2012 209 million.
At 31 December 2013, nil 2012 nil of financial assets were pledged as collateral for contingent liabilities.
Provision is made for the outcome of tax, legal and other disputes where it is both probable that the Group will suffer an outflow of funds and it is possible to make a reliable estimate of that outflow.
At 31 December 2013, other than for those disputes where provision has been made, it was not possible to make a reliable estimate of the potential outflow of funds that might be required to settle disputes where the possibility of there being an outflow was more than remote.
Descriptions of the significant tax, legal and other disputes to which the Group is a party are set out in Note 14, Taxation and Note 44, Legal proceedings.
32 Net debt 2013 2012 Listing exchange m m Current assets: Liquid investments 66 81 Cash and cash equivalents 5,534 4,184 5,600 4,265 Short-term borrowings: Bank loans and overdrafts 352 323 Commercial paper 1,491 1,748 Obligations under finance leases 27 27 4.85% US$ US Medium Term Note 2013 New York Stock Exchange 1,533 London Stock Exchange 919 4.375% US$ US Medium Term Note 2014 2,789 3,631 Long-term borrowings: 4.375% US$ US Medium Term Note 2014 London Stock Exchange 970 0.75% US$ US Medium Term Note 2015 New York Stock Exchange 601 611 3.875% European Medium Term Note 2015 London Stock Exchange 1,330 1,296 0.7% US$ US Medium Term Note 2016 New York Stock Exchange 751 1.50% US$ US Medium Term Note 2017 New York Stock Exchange 1,199 1,219 5.625% European Medium Term Note 2017 London Stock Exchange 1,038 1,013 5.65% US$ US Medium Term Note 2018 New York Stock Exchange 1,653 1,683 2.85% US$ US Medium Term Note 2022 New York Stock Exchange 1,193 1,214 2.8% US$ US Medium Term Note 2023 New York Stock Exchange 743 4.00% European Medium Term Note 2025 London Stock Exchange 618 602 3.375% European Medium Term Note 2027 London Stock Exchange 591 590 5.25% European Medium Term Note 2033 London Stock Exchange 983 982 5.375% US$ US Medium Term Note 2034 London Stock Exchange 299 305 6.375% US$ US Medium Term Note 2038 New York Stock Exchange 1,641 1,670 6.375% European Medium Term Note 2039 London Stock Exchange 694 694 5.25% European Medium Term Note 2042 London Stock Exchange 987 986 4.2% US$ US Medium Term Note 2043 New York Stock Exchange 294 4.25% European Medium Term Note 2045 London Stock Exchange 788 787 Obligations under finance leases 53 49 15,456 14,671 Net debt 12,645 14,037 174 GSK Annual Report 2013 32 Net debt continued Current assets Long-term borrowings Liquid investments are classified as available-for-sale investments.
At the year-end, GSK had long-term borrowings of 15.5 billion At 31 December 2013, they included US Treasury Notes and other 2012 14.7 billion of which 8.8 billion 2012 9.5 billion falls government bonds.
The effective interest rate on liquid investments at due in more than five years.
The average effective pre-swap interest 31 December 2013 was approximately 0.5% 2012 approximately rate of all notes in issue at 31 December 2013 was approximately 2.6%.
Liquid investment balances at 31 December 2013 earning 4.5% 2012 approximately 4.9%.
interest at floating and fixed rates amount to 65 million and Long-term borrowings repayable after five years carry interest at 1 million respectively 2012 74 million and 7 million.
The repayment dates The effective interest rate on cash and cash equivalents at 31 range from 2022 to 2045.
December 2013 was approximately 1.3% 2012 approximately Pledged assets 1.7%.
Cash and cash equivalents at 31 December 2013 earning interest at floating and fixed rates amount to 5,298 million and The Group has pledged investments in US Treasury Notes with a par 1 million respectively 2012 3,876 million and 1 million.
value of $105 million 63 million 2012 $119 million 74 million as security against irrevocable letters of credit issued on the Groups GSKs policy regarding the credit quality of cash and cash behalf in respect of the Groups self-insurance activity.
Provisions in equivalents is referred to in Note 41, Financial instruments and respect of self-insurance are included within the provisions for legal related disclosures.
and other disputes discussed in Note 29, Other provisions.
At 31 December 2013, 69 million of the Groups cash balance was Short-term borrowings held in an escrow account in connection with the Groups offer to GSK has a $10 billion 6.0 billion US commercial paper purchase shares in its Indian pharmaceutical subsidiary.
In addition, programme, of which $2.5 billion 1.5 billion was in issue at 48 million 2012 49 million of assets included in Note 22, 31 December 2013 2012 $2.9 billion 1.7 billion.
GSK also Other non-current assets, which do not form part of Net debt, were has 1.9 billion of five year committed medium-term facilities pledged as collateral against future rental payments under operating and $2.5 billion 1.5 billion of 364 day committed facilities.
lease arrangements entered into by Human Genome Sciences, Inc.
These facilities were put in place in September 2012 and prior to its acquisition by the Group.
September 2013 respectively and were undrawn at 31 December 2013.
Liquid investments, cash and cash equivalents were as shown in the table on page 174.
The weighted average interest rate on current bank loans and overdrafts at 31 December 2013 was 3.7% 2012 2.1%.
The weighted average interest rate on commercial paper borrowings at 31 December 2013 was 0.18% 2012 0.20%.
2013 2012 Finance lease obligations m m Rental payments due within one year 29 30 Rental payments due between one and two years 24 21 Rental payments due between two and three years 16 17 Rental payments due between three and four years 9 9 Rental payments due between four and five years 4 2 Rental payments due after five years 5 6 Total future rental payments 87 85 Future finance charges 7 9 Total finance lease obligations 80 76 GSK Annual Report 2013 175
